Table 1.
Characteristics of colorectal cancer patients
| Colorectal cancer patients (n = 336) | |
|---|---|
| Age, mean (SD) | 68.2 (11.5) |
| Gender | |
| Male | 180 (53.6%) |
| Female | 156 (46.4%) |
| Preoperative radiotherapy or chemoradiotherapy | |
| No | 267 (79.5%) |
| Yes | 69 (20.5%) |
| Tumour location | |
| Proximal colon | 117 (34.8%) |
| Distal colon | 71 (51.1%) |
| Rectum | 148 (44.0%) |
| WHO grade | |
| Grade 1 | 73 (21.9%) |
| Grade 2 | 217 (65.0%) |
| Grade 3 | 44 (13.2%) |
| TNM stage | |
| Stage I | 71 (21.2%) |
| Stage II | 110 (32.8%) |
| Stage III | 110 (32.8%) |
| Stage IV | 44 (13.1%) |
| Mismatch repair (MMR) enzyme screening status | |
| Deficient | 38 (11.3%) |
| Proficient | 297 (88.7%) |
| Modified Glasgow Prognostic Score | |
| 0 | 262 (78.4%) |
| 1 | 64 (19.2%) |
| 2 | 8 (2.4%) |
| Systemic inflammatory markers | |
| Serum C-reactive protein, mg/L, median (IQR) | 2.80 (0.81–8.70) |
| Serum albumin, g/L, median (IQR) | 43.0 (40.0–45.0) |
| Blood neutrophil to lymphocyte ratio, median (IQR) | 2.42 (1.73–3.29) |
| Amino acids, µmol/L, mean (SD) | |
| Alanine | 452.4 (89.1) |
| Glutamine | 488.6 (87.0) |
| Glycine | 282.1 (60.5) |
| Histidine | 57.6 (10.6) |
| Isoleucine | 55.6 (18.7) |
| Leucine | 77.8 (24.3) |
| Valine | 173.2 (49.0) |
| Phenylalanine | 84.6 (18.4) |
| Tyrosine | 57.4 (16.6) |
SD standard deviation, IQR interquartile range